{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037533","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.688286+00:00","generated_at":"2026-06-09T22:29:46.913182+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lixte expands NKI/Oncode collaboration to study LB-100 + immunotherapy in additional cancers","bullets":["Amendment 2 extends the Development Collaboration Agreement for two more years.","New focus: drug synergies of LB-100 with immunotherapy plus synthetic lethal combinations in more cancer types.","Prior two-year collaboration successfully identified LB-100 combinations for colon cancer.","Parties include Netherlands Cancer Institute and Oncode Institute, with Prof. René Bernards on Lixte's board.","No financial terms or milestones disclosed in the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037533","json":"https://secwatch.observer/filing/0001493152-23-037533.json","markdown":"https://secwatch.observer/filing/0001493152-23-037533.md","text":"https://secwatch.observer/filing/0001493152-23-037533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/0001493152-23-037533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:29:46.913182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"806eae9d75c53c6106fb2434009162c611cdddc2","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Development Collaboration Agreement Amendment 2 with Netherlands Cancer Institute (NKI) and Oncode Institute valued at Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years (effective 2023-10-13).","evidence_excerpt":"On October 13, 2023, the parties signed an amendment (“Amendment 2”) to expand the collaboration to study drug synergies of the Company’s lead compound, LB-100, with immunotherapy in various cancers. Under Amendment 2, the parties will seek to find synthetic lethal combinations in additional cancer types. Amendment 2 also extends the Collaboration Agreement for an additional two years.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/0001493152-23-037533-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Netherlands Cancer Institute (NKI) and Oncode Institute"},{"label":"Value","value":"Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years"},{"label":"Effective","value":"2023-10-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}